University Of UA Cancer Center(UACC)/DH-SJHMC
Welcome,         Profile    Billing    Logout  
 21 Trials 
35 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Jue
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04477616: Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy

Completed
2
160
RoW
Day 7 regimen, Day 3 regimen
The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
10/22
11/22
NCT04717531: Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Recruiting
2
60
RoW
Pyrotinib, B, Trastuzumab, H, Pertuzumab, P, Docetaxel, T, Epirubicin, E, Cyclophosphamide, C
The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
06/23
05/24
NCT05974449: Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients

Recruiting
2
60
RoW
Vaginal Lactobacillus capsules, Ding Jun Sheng
The First Affiliated Hospital with Nanjing Medical University
Breast Cancer Female
12/25
12/25
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NBC Sur001, NCT04482803: Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for CN+ Breast Cancer

Completed
N/A
159
RoW
Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes, A locating clip was placed in one of the suspected lymph nodes, Preoperative FNA will be performed again for locating clip labelled node
The First Affiliated Hospital with Nanjing Medical University
Location and Biopsy of Axillary Lymph Nodes
12/22
05/23
ADANC, NCT06234150: Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment

Not yet recruiting
N/A
90
RoW
Aerobic dance, Fast-walking
The First Affiliated Hospital with Nanjing Medical University
Breast Neoplasms, Exercise Therapy, Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction, Dance Therapy
07/26
01/27
NCT05935150: Omission of SLNB in CN0 Early Breast Cancer

Recruiting
N/A
311
RoW
Omit SLNB
The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node
07/27
10/27
Aggarwal, Rahul
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
PRESTO, NCT03009981: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Active, not recruiting
3
504
US
Apalutamide, Erleada, LHRH Analogue, Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide, Abiraterone Acetate, Zytiga, Prednisone, Deltasone
Alliance Foundation Trials, LLC., Janssen Research & Development, LLC
Prostate Cancer
07/25
01/26
PILLAR, NCT03503344: Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

Active, not recruiting
2
26
US
Apalutamide, ARN 509, JNJ 56021927, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
University of California, San Francisco, Janssen Pharmaceuticals
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
06/25
01/27
NCI-2018-02195, NCT03933670: Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Recruiting
2
60
US
Hyperpolarized Carbon C 13 Pyruvate, Hyperpolarized 13C-Pyruvate, Hyperpolarized Pyruvate (13C), Magnetic Resonance Spectroscopic Imaging, Hydrogen-1 (1H)- Nuclear Magnetic Resonance Spectroscopic Imaging, 1H-nuclear magnetic resonance spectroscopic imaging, Magnetic Resonance Spectroscopy, MRS, MRS Imaging, MRSI, Proton Magnetic Resonance Spectroscopic Imaging, MRI Ultrasound Fusion Guided Biopsy, Fusion Biopsy, Fusion Guided Biopsy, Fusion-Guided Biopsy, MR Fusion Biopsy, MRI-Ultrasound Fusion Biopsy, MRI/Ultrasound Fusion Biopsy, MRI/US Biopsy
University of California, San Francisco, National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Prostate Adenocarcinoma, Prostate Cancer
03/25
10/25
NCT03284385: Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Active, not recruiting
2
60
US
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
08/25
08/25
SYNERGY-201, NCT06228053: Study of SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting
2
53
US
SX-682, Enzalutamide, Xtandi
Syntrix Biosystems, Inc., National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
06/26
06/28
NCT04926181: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Active, not recruiting
2
2
US
Apalutamide, Erleada, Androgen Receptor Inhibitorsv(ARI), Apalutamide Oral Tablet, Cetrelimab, JNJ-63723283, Anti-PD-1 antibody cetrelimab (JNJ-63723283), CET
Rahul Aggarwal, Janssen Scientific Affairs, LLC
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
03/24
02/25
NCI-2018-01648, NCT03682289: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Recruiting
2
89
US
Ceralasertib, AZD-6738, AZD6738, ATR Kinase Inhibitor AZD6738, Olaparib, AZD2281, KU-0059436, Lynparza, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor AZD2281, Durvalumab, Imfimzi, MEDI4736, MEDI-4736
Rahul Aggarwal, AstraZeneca
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
09/27
09/27
NCT04346225: Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

Recruiting
2
75
US
Hyperpolarized C13, HP [1-13C]pyruvate, Magnetic Resonance Imaging (MRI), Magnetic Resonance
Ivan de Kouchkovsky, MD, National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Prostate Cancer, Advanced Prostate Carcinoma
12/25
11/26
NCT04471974: ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
54
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Enzalutamide, ASP9785, MDV3100, Xtandi, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Rahul Aggarwal, Zenith Epigenetics, Merck Sharp & Dohme LLC, U.S. Army Medical Research and Development Command
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/27
04/27
NCT05766371: Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Recruiting
2
48
US
Pembrolizumab, Keytruda, 177Lu-PSMA-617, Lutetium-177-PSMA-617, (177Lu)-PSMA-617
University of California, San Francisco, Merck Sharp & Dohme LLC, Prostate Cancer Foundation
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
05/27
05/31
DCC-3084-01-001, NCT06287463: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Recruiting
1/2
140
US
DCC-3084
Deciphera Pharmaceuticals, LLC
Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
08/26
08/27
NCT05888532: 64Cu-GRIP B in Patients With Advanced Malignancies

Recruiting
1/2
91
US
Copper-64 labeled Granzyme B (64Cu-GRIP B), 64Cu-GRIP B, 64Cu-labeled GRIP B, Positron Emission Tomography (PET), Positron Emission Tomography, PET, PET Scan
Rahul Aggarwal, National Cancer Institute (NCI), U.S. Army Medical Research Acquisition Activity
Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
12/26
01/27
NCT05011188: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
1/2
36
US
FOR46, Antibody-Drug Conjugate (ADC), anti-CD46 antibody conjugate, Enzalutamide, XTANDI, Pegfilgrastim, G-CSF, Blood Samples, Blood Specimen, Biospecimen
Rahul Aggarwal, Fortis Therapeutics, Inc., FibroGen
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
03/27
03/27
NCT03822871: A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Completed
1
17
US
CTT1403, CTT1057, 68Ga-PSMA-11
Cancer Targeted Technology, University of California, San Francisco, National Cancer Institute (NCI)
Prostate Cancer
10/22
02/23
NCT02391025: Gallium-68 Citrate PET Used in Prostate Cancer

Completed
1
39
US
Gallium-68 citrate, Gallium-68 (8^Ga) citrate, Ga-68 citrate, Positron Emission Tomography (PET), PET Scan
Rahul Aggarwal, United States Department of Defense
Prostatic Neoplasms
06/23
06/23
NCT04927663: 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Recruiting
1
26
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, 11C-YJH08, Radioactive Tag, Radioactive Tracer, Radioactive Label, Optional Tumor Biopsy, Tumor Biopsy
Rahul Aggarwal, U.S. Army Medical Research Acquisition Activity, National Institute of Mental Health (NIMH)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
10/25
10/25
NCT03590054: Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Checkmark Interim data in combination with abexinostat for multiple solid tumors
Aug 2019 - Aug 2019: Interim data in combination with abexinostat for multiple solid tumors
Completed
1
35
US
Abexinostat, PCI-24781, Pembrolizumab, Keytruda
Rahul Aggarwal, Xynomic Pharmaceuticals, Inc.
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
11/23
11/23
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
R01CA229354, NCT03805594: 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
1
43
US
Lutetium Lu 177-PSMA-617, 177Lu-PSMA-617, Lu177-PSMA-617, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of California, San Francisco, Prostate Cancer Foundation, National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
01/24
04/25
NCT02526368: Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting
1
50
US
Hyperpolarized 13C-Pyruvate, Hyperpolarized Pyruvate (13C), Hyperpolarized 13C,15N2-urea, Urea C-13, C13 Urea, Magnetic Resonance Spectroscopic Imaging, MRSI, MRS, 1H- Nuclear Magnetic Resonance Spectroscopic Imaging, MRS Imaging
Ivan de Kouchkovsky, MD, American Cancer Society, Inc., National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Prostate Cancer
12/26
12/26
NCT06014658: Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting
1
90
US
Antibody-Drug Conjugate
MBrace Therapeutics
Cancer
07/25
11/25
NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Recruiting
1
499
US
TAB004, JS004, Toripalimab, TAB001, JS001
TopAlliance Biosciences, Shanghai Junshi Bioscience Co., Ltd., CTI Clinical Trial and Consulting Services
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
03/26
03/26
NCT05127850: MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer

Completed
N/A
51
US
Consultation audio recording app, Voice Recording app, Mobile voice recording app, Smartphone voice recording app, Tablet voice recording app
University of California, San Francisco, Conquer Cancer Foundation
Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
02/24
04/24
NCI-2018-02052, NCT02735252: PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Active, not recruiting
N/A
156
US
Systemic therapy, StrataNGS
University of California, San Francisco, Prostate Cancer Foundation, Strata Oncology
Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
03/27
03/27
Tang, Bixia
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
NCT05258266: A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

Not yet recruiting
1/2
76
RoW
ZX-101A
Nanjing Zenshine Pharmaceuticals
Advanced Solid Tumor
06/23
04/24

Download Options